Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Noreen Fertig"'
Publikováno v:
The Journal of Rheumatology. 44:223-229
Objective.To evaluate the utility of anticytoplasmic autoantibody (anti-CytAb) in antisynthetase antibody–positive (anti-SynAb+) patients.Methods.Anti-SynAb+ patients were evaluated for antinuclear antibody (ANA) and anti-CytAb [cytoplasmic stainin
Autor:
Chad Stephens, Marc C. Levesque, Diane Koontz, Ilinca D. Metes, Danielle Goudeau, Chester V. Oddis, Noreen Fertig, Rohit Aggarwal, Zengbiao Qi
Publikováno v:
Rheumatology. 54:1194-1199
Objective. The aim of this study was to develop and validate a quantitative anti-signal recognition particle (SRP) autoantibody serum ELISA in patients with myositis and longitudinal association with myositis disease activity. Methods. We developed a
Autor:
Mary Lucas, Noreen Fertig, Shinichi Sato, Manabu Fujimoto, Fumihide Ogawa, Andrew Schnure, Kana Hoshino, Kazuhiko Takehara, Masataka Kuwana, Thomas A. Medsger, Takashi Satoh, Minoru Hasegawa, Kenzou Kaji, Yasuhito Hamaguchi
Publikováno v:
Arthritis Care & Research. 66:575-584
Objective To identify and characterize a novel systemic sclerosis (SSc)–related autoantibody directed against a complex consisting of RuvBL1 and RuvBL2 (RuvBL1/2) and to assess its clinical correlations. Methods We first analyzed 316 consecutive pa
Autor:
Chester V, Oddis, Ann M, Reed, Rohit, Aggarwal, Lisa G, Rider, Dana P, Ascherman, Marc C, Levesque, Richard J, Barohn, Brian M, Feldman, Michael O, Harris-Love, Diane C, Koontz, Noreen, Fertig, Stephanie S, Kelley, Sherrie L, Pryber, Frederick W, Miller, Howard E, Rockette, David, Sherry
Publikováno v:
Arthritis & Rheumatism. 65:314-324
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired disorders characterized by chronic inflammation of striated muscle leading to predominantly proximal muscle weakness. The most common subsets of IIM include adult poly
Publikováno v:
Arthritis & Rheumatism. 64:2986-2994
Objective Epidemiology studies suggest that systemic sclerosis (SSc) is more common, occurs at a younger age, and is more severe in African Americans than Caucasians. However, the scleroderma autoantibody profile is very different between these 2 eth
Autor:
Naftali Kaminski, Aaron Eggebeen, Samuel A. Yousem, Kevin F. Gibson, Dana P. Ascherman, Noreen Fertig, Carl R. Fuhrman, Thomas J. Richards, Ivan O. Rosas, Chester V. Oddis, Bernadette R. Gochuico
Publikováno v:
Arthritis & Rheumatism. 60:2183-2192
Objective Using a combination of clinical, radiographic, functional, and serum protein biomarker assessments, this study was aimed at defining the prevalence and clinical characteristics of interstitial lung disease (ILD) in a large cohort of patient
Publikováno v:
Arthritis & Rheumatism. 60:1112-1118
Objective To describe the classification, demographic and clinical features, and survival in anti–U3 RNP autoantibody–positive patients with systemic sclerosis (SSc). Methods Medical records of 108 anti–U3 RNP–positive and 2,471 anti–U3 RNP
Publikováno v:
The Journal of Rheumatology. 35:2439-2444
ObjectiveTo determine the frequency of selected serum autoantibodies and their clinical associations in patients with childhood-onset (ChO) or adult-onset (AO) linear scleroderma (LiScl) evaluated at a single institution.MethodsSeventy-two patients (
Autor:
Timothy B. Oriss, Paula R. Clemens, Yuehong Wu, Daniel Vandersteen, Andrew D. Weinberg, William M. Ridgway, Dana P. Ascherman, David L. Chin, Carlos J. Camacho, Noreen Fertig, Tim D. Oury, Xinyan Gu, Yasuhiro Katsumata
Publikováno v:
Journal of Autoimmunity. 29:174-186
Evidence implicating histidyl-tRNA synthetase (Jo-1) in the pathogenesis of the anti-synthetase syndrome includes established genetic associations linking the reproducible phenotype of muscle inflammation and interstitial lung disease with autoantibo
Autor:
Yasuhiro Katsumata, Noreen Fertig, Dana P. Ascherman, Robyn T. Domsic, Mary Lucas, Kerry B. Stone, Molly T. Vogt, Chester V. Oddis
Publikováno v:
Arthritis & Rheumatism. 56:3125-3131
Objective Previous case series have examined the relationship between anti–Jo-1 antibody levels and myositis disease activity, demonstrating equivocal results. Using enzyme-linked immunosorbent assays (ELISAs) and novel measures of myositis disease